US Supreme Court Won’t Hear “Pharma Bro’s” Case

US Supreme Court Won’t Hear “Pharma Bro’s” Case
US Supreme Court Won’t Hear “Pharma Bro’s” Case

Martin Shkreli, former CEO of the Retrophin hedge fund and Turing Pharmaceuticals, who was convicted of securities fraud and conspiracy in 2017, appears to have run out of options to get out of jail early.

Shkreli first gained notoriety in 2015 for jacking up the price of toxoplasmosis drug Daraprim by 5,000% overnight and later was accused by Retrophin investors of inflating the fund’s stock price and enriching himself on the proceeds.

Currently serving a seven-year prison sentence, Shkreli this week lost his ambitious challenge to have his case heard by the US Supreme Court. Following multiple appeals, the nation’s highest court refused to review his conviction, and he will also be unable to recover the $7.36 million he was obliged to forfeit.

This means that the “pharma bro” as he called himself, is likely to remain incarcerated for the next five years. He could be there longer, however. While the sentence on the original charges, is set to end in September 2023, US press reports say it could be extended, as Shkreli has been accused of running his business from behind bars.

The latest charge came after the US Bureau of Prisons began investigating a report by financial newspaper Wall Street Journal that the high-profile inmate was running his biotech, Phoenixus, from his cell, using a contraband mobile phone.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.